Pelthos Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THESIX MONTHS ENDED JUNE 30, 2026 AND 2025
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flow from operating activities: | ||
| Net loss | $(48,490) | $(5,417) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Accretion of interest for royalty obligations | 2,040 | — |
| Change in fair value of convertible notes | 13,337 | — |
| Depreciation of property and equipment | 747 | — |
| Amortization of intangible assets | 2,074 | — |
| Amortization of debt discount | 432 | 259 |
| Lease amortization expense | 138 | — |
| Stock-based compensation | 4,668 | 899 |
| Inventory write-off | 925 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (5,624) | — |
| Inventory | 1,374 | — |
| Prepaid expenses | 113 | 53 |
| Operating lease right-of-use assets | 209 | — |
| Accounts payable | 2,823 | 3,103 |
| Accrued expenses | 6,398 | 24 |
| Contingent consideration | (1,200) | — |
| Operating lease liabilities | (330) | — |
| Deferred revenue | (424) | — |
| Net cash used in operating activities | (20,790) | (1,079) |
| Cash flow from investing activities: | ||
| Purchases of property and equipment | (196) | — |
| Net cash used in investing activities | (196) | — |
| Cash flow from financing activities: | ||
| Proceeds from venture loan and security agreement, net | 29,337 | — |
| Proceeds from loan payable, net of debt discount | — | 625 |
| Payment of venture loan and security agreement issuance costs | (1,814) | — |
| Net cash provided by financing activities | 27,523 | 625 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 6,537 | (454) |
| Cash, cash equivalents and restricted cash as of beginning of period | 18,023 | 513 |
| Cash, cash equivalents and restricted cash as of end of period | $24,560 | $59 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THETHREE AND SIX MONTHS ENDED JUNE 30, 2026 AND 2025 (CONTINUED)
| Six Months Ended June 30, | |
| 2026 | 2025 |
| Reconciliation to condensed consolidated balance sheets: | ||
|---|---|---|
| Cash and cash equivalents | $24,192 | $59 |
| Restricted cash | 368 | — |
| Total cash, cash equivalents and restricted cash shown in the statement of cash flows | $24,560 | $59 |
| Supplemental cash flow information: | ||
|---|---|---|
| Cash paid for income taxes | $— | $— |
| Cash paid for interest expense | $1,488 | $19 |
| Supplemental non-cash investing and financing activities: | ||
| Purchases of property and equipment with accounts payable and accrued expenses | $44 | $— |
| Warrants issued for venture loan and security agreement | $1,362 | $— |
| Payment-in-kind on convertible debt | $621 | $— |
| Offering costs recorded to debt discount | $— | $39 |
| Conversion of notes to common stock | $— | $737 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.